Cargando…
Management of chronic myelogenous leukemia with COVID-19 and hepatitis B
The application of immunosuppressive agents and targeted drugs has opened a novel approach for the treatment of hematological tumors, and the application of tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia is one of the landmark breakthroughs that has considerably improved th...
| Autores principales: | , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Frontiers Media S.A.
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10438954/ https://www.ncbi.nlm.nih.gov/pubmed/37601670 http://dx.doi.org/10.3389/fonc.2023.1217023 |